- Home
- SYTA vs KPRX Comparison
SYTA vs KPRX Comparison
Compare SYTA & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYTA
- KPRX
- Stock Information
- Founded
- SYTA N/A
- KPRX 1998
- Country
- SYTA Canada
- KPRX United States
- Employees
- SYTA N/A
- KPRX N/A
- Industry
- SYTA Telecommunications Equipment
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- SYTA Telecommunications
- KPRX Health Care
- Exchange
- SYTA Nasdaq
- KPRX Nasdaq
- Market Cap
- SYTA 10.7M
- KPRX 8.6M
- IPO Year
- SYTA 2020
- KPRX N/A
- Fundamental
- Price
- SYTA $4.29
- KPRX $2.92
- Analyst Decision
- SYTA
- KPRX Strong Buy
- Analyst Count
- SYTA 0
- KPRX 1
- Target Price
- SYTA N/A
- KPRX $10.00
- AVG Volume (30 Days)
- SYTA 3.6M
- KPRX 62.3K
- Earning Date
- SYTA 08-15-2025
- KPRX 08-08-2025
- Dividend Yield
- SYTA N/A
- KPRX N/A
- EPS Growth
- SYTA N/A
- KPRX N/A
- EPS
- SYTA N/A
- KPRX N/A
- Revenue
- SYTA $11,740,024.00
- KPRX $20,000.00
- Revenue This Year
- SYTA $18.41
- KPRX N/A
- Revenue Next Year
- SYTA N/A
- KPRX N/A
- P/E Ratio
- SYTA N/A
- KPRX N/A
- Revenue Growth
- SYTA 33.58
- KPRX N/A
- 52 Week Low
- SYTA $0.93
- KPRX $2.51
- 52 Week High
- SYTA $162.90
- KPRX $4.86
- Technical
- Relative Strength Index (RSI)
- SYTA 62.85
- KPRX 46.55
- Support Level
- SYTA $3.70
- KPRX $2.68
- Resistance Level
- SYTA $4.68
- KPRX $2.96
- Average True Range (ATR)
- SYTA 0.63
- KPRX 0.17
- MACD
- SYTA 0.22
- KPRX 0.00
- Stochastic Oscillator
- SYTA 73.46
- KPRX 47.06
About SYTA Siyata Mobile Inc.
Siyata Mobile Inc is engaged in the sale of vehicle mounted, cellular-based communications platforms over advanced 3G (Third generation) mobile networks and cellular booster systems. The company develops, markets and sells a portfolio of rugged handheld Push-to-Talk over Cellular (PoC) smartphone devices. These rugged business-to-business (B2B) environments are focused on enterprise customers, first responders, construction workers, security guards, government agencies, utilities, transportation and waste management, amusement parks, and mobile workers in multiple industries. The company operates in USA, Canada, EMEA and Australia. It derives maximum revenue from USA.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.